This personalized approach ensures that our treatment plans are tailored to meet the specific needs of each individual, optimizing the potential for recovery and health improvement
3, pp276 [online] Available at: (accessed 4th April 2022) Mohanty, P.K., Kapoor, S., Dubey, A.P., Pandey, S., Shah, R., Nayak, H.K
Today, there is real-world evidence of GLP-1 receptor agonists improving the lives of people with type 1 diabetes
Compounding status is not the same as FDA approval: Even if a clinic or pharmacy markets a blend, that does not make it an FDA-approved medication
25, UF researchers studied Medicare claims data of older adults with Type 2 diabetes to assess their risk of depression while undergoing treatment with either GLP-1RAs, SGLT2is or DPP4is